However, treatment with saroglitazar or BrMSCs initiated 14 days after pulmonary fibrosis induction significantly (p < 0.05) reduced the IL-1β concentration and increased IL-10 levels compared to their levels in BLM-G. Here, IL1B is linked to pulmonary fibrosis.